Panacea Biotec Board of Directors
Get the latest insights into the leadership at Panacea Biotec. Learn about the experienced professionals guiding the company's strategy and governance.
| Name | Position |
|---|---|
| Ankit Jain | Company Secretary and Compliance Officer |
| Rajesh Jain | Chairman & Managing Director |
| Sandeep Jain | Joint Managing Director |
| Ankesh Jain | Whole Time Director |
| Harshet Jain | Whole Time Director |
| Sanjay Trehan | Executive Director - Technical & Compliances |
| Ambika Sharma | Non Executive Independent Director |
| Krishan Kumar Jalan | Non Executive Independent Director |
| Rajender Pal Singh | Non Executive Independent Director |
| Venkatesh Sarvasiddhi | Non Executive Independent Director |
Panacea Biotec FAQs
The board at Panacea Biotec consists of experienced professionals, including Ankit Jain, Rajesh Jain, and others, overseeing the company’s strategic and corporate governance.
Directors at Panacea Biotec are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.
As of the latest update, Ankit Jain is the current chairman at Panacea Biotec.
Executive directors at Panacea Biotec are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.
Yes, Panacea Biotec adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.
At Panacea Biotec, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.
